229 related articles for article (PubMed ID: 29301348)
1. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.
Liu KY; Wang LT; Hsu SH
Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29301348
[TBL] [Abstract][Full Text] [Related]
2. Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Wang LT; Chiou SS; Chai CY; Hsi E; Wang SN; Huang SK; Hsu SH
Oncotarget; 2017 Jan; 8(5):7489-7501. PubMed ID: 27283490
[TBL] [Abstract][Full Text] [Related]
3. Roles and regulation of histone acetylation in hepatocellular carcinoma.
Xia JK; Qin XQ; Zhang L; Liu SJ; Shi XL; Ren HZ
Front Genet; 2022; 13():982222. PubMed ID: 36092874
[TBL] [Abstract][Full Text] [Related]
4. Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions.
Tsai CH; Li CH; Liao PL; Chang YW; Cheng YW; Kang JJ
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118564. PubMed ID: 31672612
[TBL] [Abstract][Full Text] [Related]
5. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
6. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
[TBL] [Abstract][Full Text] [Related]
7. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase HDAC8 Promotes Insulin Resistance and β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Tian Y; Wong VW; Wong GL; Yang W; Sun H; Shen J; Tong JH; Go MY; Cheung YS; Lai PB; Zhou M; Xu G; Huang TH; Yu J; To KF; Cheng AS; Chan HL
Cancer Res; 2015 Nov; 75(22):4803-16. PubMed ID: 26383163
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity.
Fu Y; Zhang P; Ge J; Cheng J; Dong W; Yuan H; Du Y; Yang M; Sun R; Jiang H
Int J Biochem Cell Biol; 2014 Sep; 54():68-77. PubMed ID: 25019367
[TBL] [Abstract][Full Text] [Related]
10. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors.
Mork CN; Faller DV; Spanjaard RA
Curr Pharm Des; 2005; 11(9):1091-104. PubMed ID: 15853658
[TBL] [Abstract][Full Text] [Related]
11. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line.
Chidambaram A; Sundararaju K; Chidambaram RK; Subbiah R; Jayaraj JM; Muthusamy K; Vilwanathan R
J Cell Physiol; 2018 Jul; 233(7):5293-5309. PubMed ID: 29215703
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases function as novel potential therapeutic targets for cancer.
Zhang H; Shang YP; Chen HY; Li J
Hepatol Res; 2017 Feb; 47(2):149-159. PubMed ID: 27457249
[TBL] [Abstract][Full Text] [Related]
15. Chemical Tools with Fluorescence Switches for Verifying Epigenetic Modifications.
Hori Y; Kikuchi K
Acc Chem Res; 2019 Oct; 52(10):2849-2857. PubMed ID: 31577127
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylases.
Huang Y; Shaw PG; Davidson NE
Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
[TBL] [Abstract][Full Text] [Related]
17. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
Chan DW; Lee JM; Chan PC; Ng IO
Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization, and evaluation of Cd[L-proline]
Chidambaram A; Sekar A; S H K; Chidambaram RK; Arunachalam K; G P S; Vilwanathan R
Invest New Drugs; 2017 Dec; 35(6):691-705. PubMed ID: 28776290
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex.
Kai L; Samuel SK; Levenson AS
Int J Cancer; 2010 Apr; 126(7):1538-48. PubMed ID: 19810103
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors and cancer therapy.
Atadja PW
Prog Drug Res; 2011; 67():175-95. PubMed ID: 21141730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
